Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 19, 2015, Pages 5997-6002

  Schoch, Angela ^a   Kettenberger, Hubert ^a   Mundigl, Olaf ^b   Winter, Gerhard ^c   Engert, Julia ^c   Heinrich, Julia ^a   Emrich, Thomas ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibody; Charge; Engineering; FcRn; Pharmacokinetics

Indexed keywords

BRIAKINUMAB; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 12; INTERLEUKIN 23; USTEKINUMAB; ANTIBODY; BETA 2 MICROGLOBULIN; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; PROTEIN BINDING;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; CONFOCAL MICROSCOPY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIC STRENGTH; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTIGEN ANTIBODY REACTION; CHEMISTRY; PH; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; STATIC ELECTRICITY; TRANSGENIC MOUSE;

MUS MUSCULUS;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGEN-ANTIBODY REACTIONS; BETA 2-MICROGLOBULIN; CHROMATOGRAPHY, AFFINITY; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; RECEPTORS, FC; STATIC ELECTRICITY; SURFACE PLASMON RESONANCE; USTEKINUMAB;

EID: 84929190423     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1408766112     Document Type: Article

References (45)

1. Edelman GM (1991) Antibody structure and molecular immunology. Scand J Immunol 34(1):1-22.
2. Reff ME, Heard C (2001) A review of modifications to recombinant antibodies: Attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 40(1):25-35.
3. Waldmann TA, Strober W (1969) Metabolism of immunoglobulins. Prog Allergy 13: 1-110.
4. Ghetie V, Ward ES (2000) Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 18:739-766.
5. Chaudhury C, et al. (2003) The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197(3):315-322.
6. Qiao SW, et al. (2008) Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 105(27):9337-9342.
7. Roopenian DC, et al. (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170(7):3528-3533.
8. Simister NE, Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337(6203):184-187.
9. Kuo TT, et al. (2010) Neonatal Fc receptor: From immunity to therapeutics. J Clin Immunol 30(6):777-789.
10. Roopenian DC, Akilesh S (2007) FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715-725.
11. Martin WL, West AP, Jr, Gan L, Bjorkman PJ (2001) Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding. Mol Cell 7(4): 867-877.
12. Goebl NA, et al. (2008) Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 19(12):5490-5505.
13. Kim JK, Tsen MF, Ghetie V, Ward ES (1994) Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol 24(3):542-548.
14. Sánchez LM, Penny DM, Bjorkman PJ (1999) Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry 38(29):9471-9476.
15. Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ (1993) Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol 230(3): 1077-1083.
16. Ober RJ, Martinez C, Lai X, Zhou J, Ward ES (2004) Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level. Proc Natl Acad Sci USA 101(30):11076-11081.
17. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES (2004) Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 172(4): 2021-2029.
18. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 179(7):4580-4588.
19. Montoyo HP, et al. (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA 106(8):2788-2793.
20. Rodewald R (1976) pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 71(2):666-669.
21. Vaccaro C, Zhou J, Ober RJ, Ward ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23(10):1283-1288.
22. Suzuki T, et al. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184(4):1968-1976.
23. Wang W, et al. (2011) Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 39(9): 1469-1477.
24. Schlothauer T, et al. (2013) Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs 5(4):576-586.
25. Gandhi M, Alwawi E, Gordon KB (2010) Anti-p40 antibodies ustekinumab and briakinumab: Blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 29(1):48-52.
26. Zhu Y, et al. (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162-175.
27. Lima XT, Abuabara K, Kimball AB, Lima HC (2009) Briakinumab. Expert Opin Biol Ther 9(8):1107-1113.
28. Weger W (2010) Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 160(4):810-820.
29. Luo J, et al. (2010) Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 402(5):797-812.
30. Israelachvili JN (1985) Intermolecular and Surface Forces (Academic, New York).
31. Tzaban S, et al. (2009) The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol 185(4):673-684.
32. Petkova SB, et al. (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. Int Immunol 18(12):1759-1769.
33. Dall'Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281(33):23514-23524.
34. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL (2002) Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm 17(4):359-370.
35. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM (2010) Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 28(10):509-516.
36. Igawa T, et al. (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23(5):385-392.
37. Boswell CA, et al. (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21(12):2153-2163.
38. Roopenian DC, Christianson GJ, Sproule TJ (2010) Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 602:93-104.
39. Yeung YA, et al. (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates. J Immunol 182(12): 7663-7671.
40. Prabhat P, et al. (2007) Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci USA 104(14):5889-5894.
41. Lampson MA, Schmoranzer J, Zeigerer A, Simon SM, McGraw TE (2001) Insulinregulated release from the endosomal recycling compartment is regulated by budding of specialized vesicles. MolBiolCell12(11):3489-3501.
42. Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES (2009) Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 10(5):600-614.
43. Ward ES, et al. (2005) From sorting endosomes to exocytosis: Association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell 16(4): 2028-2038.
44. Christianson GJ, et al. (2012) Monoclonal antibodies directed against human FcRn and their applications. MAbs 4(2):208-216.
45. Edelman GM, et al. (1969) The covalent structure of an entire γG immunoglobulin molecule. Proc Natl Acad Sci USA 63(1):78-85.